Millennium Management’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Millennium Management’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-50,285	Closed	-$34K	–	7785
2022 Q1	$34K	Sell	50,285 -84,742	-63%	-$93K	﹤0.01%	6514
2021 Q4	$312K	Buy	135,027 +86,468	+178%	+$293K	﹤0.01%	5497
2021 Q3	$222K	Sell	48,559 -45,755	-49%	-$201K	﹤0.01%	6049
2021 Q2	$419K	Buy	+94,314	New	+$480K	﹤0.01%	5451
2021 Q1	–	Sell	-59,132	Closed	-$451K	–	6677
2020 Q4	$451K	Buy	59,132 +43,554	+280%	+$291K	﹤0.01%	4276
2020 Q3	$141	Buy	+15,578	New	+$118K	﹤0.01%	4158

Other funds holding LOGC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

HCA

Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management's LOGC Position: Q2 2022 in Review

Millennium Management sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q2 2022, closing a stake of 50,285 shares — an estimated $34K sold.

Millennium Management first reported a position in LOGC in Q3 2020 and held it in 6 quarters. The position peaked at $451K in Q4 2020. 47 funds tracked by Wall St. Rank hold LOGC as of Q2 2022.

Millennium Management reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Millennium Management sold 50,285 LogicBio Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $34K.
Millennium Management first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
Millennium Management's LogicBio Therapeutics, Inc. Common Stock position peaked at $451K in Q4 2020.
47 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Millennium Management's 13F filing for Q2 2022, filed 15 Aug 2022.